Hims & Hers Health Inc Stock Price, News & Analysis

Hims & Hers Health has launched new skincare offerings, including the Hims Overnight Anti-Aging Duo and Hers Clear Skin System. The Overnight Anti-Aging Duo features a customizable prescription Anti-Aging Cream and a nonprescription Goodnight Wrinkle Cream targeted at wrinkles and sun damage. The Hers Clear Skin System offers a customizable prescription acne cream alongside hydrating cleanser and moisturizer. Both products emphasize individual customization through consultations with healthcare providers, enhancing the company's telehealth service model.

Hims & Hers Health has launched a new D-Mannose dietary supplement, aimed at improving urinary tract health for women. Available on ForHers.com, this product comes in single-serve packets that combine D-Mannose, vitamins, and electrolytes. The initiative addresses a significant health need, as 30-40% of women experiencing a urinary tract infection will have another within six months. This highlights the company's commitment to providing holistic health solutions that are accessible and user-friendly.

Hims & Hers announced a strategic partnership with REVOLVE, allowing a diverse range of health and wellness products to be sold on REVOLVE.com. This collaboration targets Millennial and Generation Z consumers by offering affordable skincare, hair care, sleep supplements, and sexual health products. Both companies aim to enhance their brands' appeal in the consumer health and fashion sectors. This partnership follows Hims & Hers' role as the exclusive wellness partner at REVOLVE's New York Fashion Week events, further solidifying their joint brand outreach.

Hims & Hers Health, Inc. (NYSE:HIMS) announced participation in two significant conferences. The first is Citi's 2021 Virtual Global Technology Conference from September 13-15, with individual investor meetings on September 14. The second is the Raymond James Consumer Conference on September 14, featuring a live webcast with CEO Andrew Dudum at 4:20 PM ET. Hims & Hers, founded in November 2017, is a telehealth platform connecting consumers to healthcare professionals across the U.S., offering a range of health and wellness products.

Hims & Hers Health, Inc. (NYSE: HIMS) has partnered with NFL tight end Rob Gronkowski to raise awareness about men’s health issues, including mental health and hair loss. Gronkowski emphasizes the importance of prioritizing health and addresses the difficulties men face in seeking care. Hims provides a range of personalized health solutions, offering telehealth consultations and products for conditions related to mental health, sexual wellness, and more. The partnership aims to destigmatize men's health discussions and encourage proactive health management.

Hims & Hers Health announces that CFO Spencer Lee will step down, leading a six-month transition plan while a search for a new CFO begins. Co-Founder Andrew Dudum and Board Member David Wells are overseeing this search. The company reaffirms its financial guidance for Q3 and FY 2021, following impressive growth: 80% revenue increase in 2020, with Q1 and Q2 2021 revenues up 74% and 69% year-over-year respectively. Subscriptions surged 76% to 453,000, as Hims & Hers focuses on expanding services.

Hims & Hers Health, Inc. (NYSE: HIMS) has appointed Mike Chi as its first Chief Growth Officer, focusing on growth across its telehealth platform. Under Chi's leadership, the company aims to expand services, particularly in women’s health and mental health, building on a revenue increase of 80% in 2020 and strong Q1 and Q2 results, with year-over-year growth rates of 74% and 69%, respectively. The company also acquired Apostrophe and Honest Health to support growth in dermatology and UK markets.

Hims & Hers Health, Inc. reported Q2 2021 revenue of $60.7 million, a 69% increase year-over-year. The net loss widened to $(9.2) million compared to $(1.0) million a year earlier, despite a gross margin improvement to 78%. Subscriptions rose to 453,000, with 786,000 net orders recorded. The company's acquisitions of Apostrophe and Honest Health are anticipated to accelerate growth in new markets. For Q3 2021, revenue guidance is set at $69-$71 million, with Adjusted EBITDA forecasted at $(9)-(11) million for the quarter and $(35)-(40) million for the full year.

Hims & Hers Health, Inc. (NYSE: HIMS) will release its fiscal Q2 financial results on August 11, 2021, after market close, followed by a conference call at 5:00 p.m. E.T. Investors can access the call by dialing (833) 900-2256 for U.S. participants or (236) 714-2727 internationally, using conference ID # 9972259. A live audio webcast will also be available, with a replay shortly after the call. Hims & Hers offers a telehealth platform connecting consumers with licensed healthcare professionals across various medical fields, providing accessible care across all 50 states.